-
Fabhalta and Vanrafia Phase III analyses, Fabhalta real-world treatment pattern data, and zigakibart Phase I/II trial showcase strength of IgA nephropathy (IgAN) portfolio
-
C3 glomerulopathy (C3G) studies add to body of evidence of Fabhalta long-term safety and efficacy profile in native and post-transplant disease recurrence patients
-
V-INCEPTION analyses highlight Leqvio adherence and goal attainment data when initiated early in post-acute coronary syndrome patients
-
Lp(a) data underscore importance of early detection of this independent CVD risk factor in premature ASCVD patients and potential benefit of Lp(a)-targeted therapies
Basel, November 4, 2025 – Novartis will present new data from 33 abstracts across its Cardiovascular, Renal, and Metabolic (CRM) disease portfolio at the upcoming American Society of Nephrology (ASN) Kidney Week 2025 in Houston, Texas and American Heart Association's (AHA) Scientific Sessions 2025 in New Orleans, Louisiana, advancing scientific insight into these critical disease areas.
“Novartis will present a broad range of data at ASN and AHA demonstrating innovation and commitment to advancing therapies that address root causes of heart and kidney conditions,” said Ruchira Glaser, M.D., Global Head, Cardiovascular, Renal and Metabolic Development Unit, Novartis. "Studies on both our approved and investigational therapies in these closely connected therapeutic areas reflect our longstanding dedication to deliver meaningful solutions for patients living with some of the rarest to most prevalent CRM diseases worldwide.”
Key highlights of data accepted by ASN include:
Abstract Title
Fabhalta® (iptacopan)
Efficacy and Safety of Iptacopan in Patients (Pts) from East Asia with IgAN: Interim Results from the Phase 3 APPLAUSE-IgAN Trial
Early Insights into Characteristics and Treatment Patterns of US Patients (Pts) with IgAN Who Were Prescribed Iptacopan: The APPRISE-IgAN Data Platform
Efficacy and Safety of Iptacopan in Patients with C3 Glomerulopathy: C3G Extension Trial Interim Results from the Phase 3 APPEAR-C3G Patients
Update to the Long-Term Efficacy and Safety of Iptacopan in C3 Glomerulopathy: 39-Month Phase 2 Extension Study Data
Iptacopan Treatment in Patients with C3 Glomerulopathy (C3G): 12-Month Results from the Early Access Program
Vanrafia® (atrasentan)
Renin-Angiotensin System Inhibitor (RASi) Use and Atrasentan in IgAN: Post Hoc Analysis from the ALIGN Trial
Efficacy and Safety of Atrasentan in Patients (Pts) with IgAN from East (E) Asia: Phase 3 ALIGN Interim Data
Zigakibart
Long-Term Stabilization of Kidney Function Regardless of Baseline eGFR and Urine Protein-to-Creatinine Ratio (UPCR) in Patients with IgAN: Subgroup Analyses from the Phase 1/2 Trial of Zigakibart
SHIFT: A Kidney Biopsy Study in Adults with IgAN Treated with Zigakibart
Farabursen
Farabursen Increases Urinary Polycystin-1 and Polycystin-2 and Reduces Height-Adjusted Total Kidney Volume Growth in Patients with ADPKD
Key highlights of data accepted by AHA include:
Abstract Title
Leqvio® (inclisiran)*
Effect Of Inclisiran-based Treatment Strategy, In Combination With Individually Optimized Statin Therapy, On Quality Of Life And Muscle-related Pain vs. Standard of Care: Exploratory Outcomes From The VICTORION-Difference Study
VICTORION-INCEPTION: Adherence and Goal Attainment Data Support the Addition of Inclisiran to Background Lipid-Lowering Therapy as a Lipid Management Strategy Post-Acute Coronary Syndrome
VICTORION-INCEPTION: Consistent Low-Density Lipoprotein Cholesterol Lowering With Inclisiran Following Acute Coronary Syndrome Independent of Index Lipid-Lowering Therapy
Primary Results of the VICTORION-NOVEL (LDL-C maNagement PrOgram in Atherosclerotic Cardiovascular Disease (ASCVD) Patients with Elevated LDL-C) Lipid Optimization Multicenter Implementation Trial
Lipoprotein(a)
Overcoming Barriers For Research Participation In Minority Patients In Lp(a)FRONTIERS EXPANSION: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate Efficacy And Safety Of Pelacarsen In U.S. Black And Hispanic Patients with Elevated Lp(a) And Established ASCVD
Elevated Lipoprotein(a) Is Independently Associated With Greater Infarct Size, Especially in Premature Atherosclerosis
Impact of Elevated Lipoprotein(a) on Cardiovascular Events in Patients with premature ASCVD: A Nationally Representative Sample of US Medicare, Medicaid, and Commercial Enrollees
Pacibekitug**
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Monthly or Quarterly Subcutaneous Administration of the Interleukin-6 Inhibitor Pacibekitug in Patients With Elevated High-Sensitivity C-Reactive Protein and Chronic Kidney Disease: 90-Day Analyses from TRANQUILITY
About Novartis
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide.
Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram.
*Novartis has obtained global rights to develop, manufacture and commercialize Leqvio under a license and collaboration agreement with Alnylam Pharmaceuticals, a leader in RNAi therapeutics.
**Complementing its cardiovascular pipeline, Novartis recently acquired Tourmaline Bio, a clinical-stage biopharmaceutical company developing pacibekitug, a Phase III-ready anti-IL-6monoclonal antibody for atherosclerotic cardiovascular disease (ASCVD).